Globenewswire·2026-03-10 21:34Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Nektar Therapeutics securities during the specified Class Period from February 26, 2025, to December 15, 2025, due to alleged misleading statements and failures to disclose critical information regarding the REZOLVE-AA trial [1][5]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false and/or misleading statements and failed to disclose that enrollment in the REZOLVE-AA trial did not follow applicable instructions and protocol standards [5]. - It is alleged that this failure likely had a significant negative impact on the results of the REZOLVE-AA trial, overstating its overall integrity and prospects [5]. - The lawsuit asserts that when the true details became known, investors suffered damages as a result of the misleading public statements [5]. Group 2: Participation Information - Investors who purchased Nektar securities during the Class Period may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must move the Court by May 5, 2026, to represent other class members in directing the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. - Many attorneys at the firm have received recognition from Lawdragon and Super Lawyers, highlighting their expertise in this area [4].